Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvix PDT in High Risk Basal Cell Carcinoma
NCT00473343Phase 3Completed
- Sponsor
- Galderma
- Start
- Sep 2000
- Primary completion
- Jun 2006
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of methyl aminolevulinate in basal cell carcinoma (BCC), sponsored by Galderma. Started Sep 2000; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT00473343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00473343.